Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVD vs RVD + ASCT in Newly Diagnosed Multiple Myeloma
NCT01208662Phase 3Active, not recruiting
- Start
- Sep 2010
- Primary completion
- Feb 2022
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of lenalidomide, bortezomib, dexamethasone in multiple myeloma (MM). Started Sep 2010; status: active, not recruiting.
02
Drugs
lenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01208662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01208662.